MedTrace Logo

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

NCT06613633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment, the characteristics of the distribution of lesions when the best response is achieved, the feasibility of SRT when the best response is achieved, and the phenotype of disease progression after EGFR-TKI resistance.

In summary, this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI, which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC.

Conditions

  • Third-generation TKI
  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG

third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Wuhan TongJi Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2024-08-01
Completion
2026-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613633 on ClinicalTrials.gov